Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $9.6 million.

  • Amylyx Pharmaceuticals' Gains from Investment Securities rose 1504.37% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year increase of 1504.37%. This contributed to the annual value of $7.7 million for FY2024, which is 2132.23% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Gains from Investment Securities is $9.6 million, which was up 1504.37% from $9.8 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Gains from Investment Securities registered a high of $10.7 million during Q2 2024, and its lowest value of -$1.9 million during Q2 2021.
  • For the 5-year period, Amylyx Pharmaceuticals' Gains from Investment Securities averaged around $5.8 million, with its median value being $8.2 million (2022).
  • In the last 5 years, Amylyx Pharmaceuticals' Gains from Investment Securities soared by 54884.42% in 2022 and then plummeted by 9304.29% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $1.7 million in 2021, then skyrocketed by 382.35% to $8.2 million in 2022, then tumbled by 73.17% to $2.2 million in 2023, then decreased by 16.95% to $1.8 million in 2024, then skyrocketed by 425.39% to $9.6 million in 2025.
  • Its Gains from Investment Securities stands at $9.6 million for Q3 2025, versus $9.8 million for Q2 2025 and $100000.0 for Q1 2025.